vs
EPAM Systems（EPAM）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
EPAM Systems的季度营收约是Revvity的1.8倍（$1.4B vs $772.1M），Revvity净利率更高（12.7% vs 7.8%，领先5.0%），EPAM Systems同比增速更快（12.8% vs 5.9%），EPAM Systems自由现金流更多（$268.1M vs $161.8M），过去两年EPAM Systems的营收复合增速更高（9.9% vs 9.0%）
EPAM Systems是总部位于美国宾夕法尼亚州纽敦的企业，核心业务涵盖软件工程服务、数字平台研发、数字产品设计三大板块，同时是MACH联盟的创始成员，在全球数字化服务赛道拥有深厚的技术积累与行业认可度。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
EPAM vs RVTY — 直观对比
营收规模更大
EPAM
是对方的1.8倍
$772.1M
营收增速更快
EPAM
高出6.9%
5.9%
净利率更高
RVTY
高出5.0%
7.8%
自由现金流更多
EPAM
多$106.3M
$161.8M
两年增速更快
EPAM
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $772.1M |
| 净利润 | $109.4M | $98.4M |
| 毛利率 | 30.1% | — |
| 营业利润率 | 10.6% | 14.5% |
| 净利率 | 7.8% | 12.7% |
| 营收同比 | 12.8% | 5.9% |
| 净利润同比 | 5.9% | 3.9% |
| 每股收益（稀释后） | $1.97 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EPAMRVTY
| Q4 25 | $1.4B | $772.1M | ||
| Q3 25 | $1.4B | $698.9M | ||
| Q2 25 | $1.4B | $720.3M | ||
| Q1 25 | $1.3B | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.2B | $684.0M | ||
| Q2 24 | $1.1B | $691.7M | ||
| Q1 24 | $1.2B | $649.9M |
净利润EPAMRVTY
| Q4 25 | $109.4M | $98.4M | ||
| Q3 25 | $106.8M | $46.7M | ||
| Q2 25 | $88.0M | $53.9M | ||
| Q1 25 | $73.5M | $42.2M | ||
| Q4 24 | $103.3M | $94.6M | ||
| Q3 24 | $136.3M | $94.4M | ||
| Q2 24 | $98.6M | $55.4M | ||
| Q1 24 | $116.2M | $26.0M |
毛利率EPAMRVTY
| Q4 25 | 30.1% | — | ||
| Q3 25 | 29.5% | 53.6% | ||
| Q2 25 | 28.8% | 54.5% | ||
| Q1 25 | 26.9% | 56.5% | ||
| Q4 24 | 30.4% | — | ||
| Q3 24 | 34.6% | 56.3% | ||
| Q2 24 | 29.3% | 55.7% | ||
| Q1 24 | 28.4% | 54.6% |
营业利润率EPAMRVTY
| Q4 25 | 10.6% | 14.5% | ||
| Q3 25 | 10.4% | 11.7% | ||
| Q2 25 | 9.3% | 12.6% | ||
| Q1 25 | 7.6% | 10.9% | ||
| Q4 24 | 10.9% | 16.3% | ||
| Q3 24 | 15.2% | 14.3% | ||
| Q2 24 | 10.5% | 12.4% | ||
| Q1 24 | 9.5% | 6.8% |
净利率EPAMRVTY
| Q4 25 | 7.8% | 12.7% | ||
| Q3 25 | 7.7% | 6.7% | ||
| Q2 25 | 6.5% | 7.5% | ||
| Q1 25 | 5.6% | 6.4% | ||
| Q4 24 | 8.3% | 13.0% | ||
| Q3 24 | 11.7% | 13.8% | ||
| Q2 24 | 8.6% | 8.0% | ||
| Q1 24 | 10.0% | 4.0% |
每股收益（稀释后）EPAMRVTY
| Q4 25 | $1.97 | $0.86 | ||
| Q3 25 | $1.91 | $0.40 | ||
| Q2 25 | $1.56 | $0.46 | ||
| Q1 25 | $1.28 | $0.35 | ||
| Q4 24 | $1.80 | $0.77 | ||
| Q3 24 | $2.37 | $0.77 | ||
| Q2 24 | $1.70 | $0.45 | ||
| Q1 24 | $1.97 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.7B | $7.3B |
| 总资产 | $4.9B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EPAMRVTY
| Q4 25 | $1.3B | $919.9M | ||
| Q3 25 | $1.2B | $931.4M | ||
| Q2 25 | $1.0B | $991.8M | ||
| Q1 25 | $1.2B | $1.1B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $2.1B | $1.2B | ||
| Q2 24 | $1.8B | $2.0B | ||
| Q1 24 | $2.0B | $1.7B |
股东权益EPAMRVTY
| Q4 25 | $3.7B | $7.3B | ||
| Q3 25 | $3.7B | $7.4B | ||
| Q2 25 | $3.7B | $7.6B | ||
| Q1 25 | $3.6B | $7.6B | ||
| Q4 24 | $3.6B | $7.7B | ||
| Q3 24 | $3.6B | $7.9B | ||
| Q2 24 | $3.4B | $7.9B | ||
| Q1 24 | $3.5B | $7.8B |
总资产EPAMRVTY
| Q4 25 | $4.9B | $12.2B | ||
| Q3 25 | $4.8B | $12.1B | ||
| Q2 25 | $4.7B | $12.4B | ||
| Q1 25 | $4.7B | $12.4B | ||
| Q4 24 | $4.8B | $12.4B | ||
| Q3 24 | $4.5B | $12.8B | ||
| Q2 24 | $4.2B | $13.4B | ||
| Q1 24 | $4.4B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $282.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $268.1M | $161.8M |
| 自由现金流率自由现金流/营收 | 19.0% | 21.0% |
| 资本支出强度资本支出/营收 | 1.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.59× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $612.7M | $509.4M |
8季度趋势，按日历期对齐
经营现金流EPAMRVTY
| Q4 25 | $282.9M | $182.0M | ||
| Q3 25 | $294.7M | $138.5M | ||
| Q2 25 | $53.2M | $134.3M | ||
| Q1 25 | $24.2M | $128.2M | ||
| Q4 24 | $130.3M | $174.2M | ||
| Q3 24 | $242.0M | $147.9M | ||
| Q2 24 | $57.0M | $158.6M | ||
| Q1 24 | $129.9M | $147.6M |
自由现金流EPAMRVTY
| Q4 25 | $268.1M | $161.8M | ||
| Q3 25 | $286.4M | $120.0M | ||
| Q2 25 | $43.4M | $115.5M | ||
| Q1 25 | $14.8M | $112.2M | ||
| Q4 24 | $114.5M | $149.8M | ||
| Q3 24 | $237.0M | $125.6M | ||
| Q2 24 | $52.3M | $136.6M | ||
| Q1 24 | $123.2M | $129.7M |
自由现金流率EPAMRVTY
| Q4 25 | 19.0% | 21.0% | ||
| Q3 25 | 20.5% | 17.2% | ||
| Q2 25 | 3.2% | 16.0% | ||
| Q1 25 | 1.1% | 16.9% | ||
| Q4 24 | 9.2% | 20.5% | ||
| Q3 24 | 20.3% | 18.4% | ||
| Q2 24 | 4.6% | 19.7% | ||
| Q1 24 | 10.6% | 20.0% |
资本支出强度EPAMRVTY
| Q4 25 | 1.1% | 2.6% | ||
| Q3 25 | 0.6% | 2.6% | ||
| Q2 25 | 0.7% | 2.6% | ||
| Q1 25 | 0.7% | 2.4% | ||
| Q4 24 | 1.3% | 3.4% | ||
| Q3 24 | 0.4% | 3.3% | ||
| Q2 24 | 0.4% | 3.2% | ||
| Q1 24 | 0.6% | 2.7% |
现金转化率EPAMRVTY
| Q4 25 | 2.59× | 1.85× | ||
| Q3 25 | 2.76× | 2.97× | ||
| Q2 25 | 0.60× | 2.49× | ||
| Q1 25 | 0.33× | 3.03× | ||
| Q4 24 | 1.26× | 1.84× | ||
| Q3 24 | 1.77× | 1.57× | ||
| Q2 24 | 0.58× | 2.87× | ||
| Q1 24 | 1.12× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EPAM
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
